Might cholesterol sulfate deficiency contribute to the development of autistic spectrum disorder?

Medical Hypotheses

Volumn 78, Issue 2, 2012, Pages 213-217

  Seneff, Stephanie ^a   Davidson, Robert ^b   Mascitelli, Luca ^c  

^a Department of Electrical Engineering and Computer Science   (United States)

^b PhyNet Inc   (United States)

^c Medical Service   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 DEHYDROEPIOANDROSTERONE; ANDROSTERONE DERIVATIVE; CASEIN; CHOLESTEROL SULFATE; CYSTEINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; FILAGGRIN; GLUTATHIONE; LOW DENSITY LIPOPROTEIN; OPIATE; PARACETAMOL; SULFUR; TAURINE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ARTICLE; ASTHMA; AUTISM; BLOOD BRAIN BARRIER; CHOLESTEROL SULFATE DEFICIENCY; CHOLESTEROL TRANSPORT; DETOXIFICATION; DIGESTIVE SYSTEM DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ECZEMA; FETUS DEVELOPMENT; GLUTEN FREE DIET; HUMAN; IMMUNE RESPONSE; METABOLIC DISORDER; MOTHER; PERINATAL PERIOD; PREGNANCY; SUN EXPOSURE;

ANDROSTERONE; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHOLESTEROL ESTERS; DIET; ESTROGENS; FEMALE; HUMANS; IMMUNE SYSTEM; MATERNAL EXPOSURE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PREGNANCY; PREGNANCY COMPLICATIONS; SULFATES; SULFUR; SUNLIGHT;

EID: 84855194896     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.10.026     Document Type: Article

References (60)

1. Dawson G., Toth K., Abbott R., et al. Early social attention impairments in autism: social orienting, joint attention, and attention to distress. Dev Psychol 2004, 40(2):271-283.
2. Castellani M.L., Conti C.M., Kempuraj D.J., et al. Autism and immunity: revisited study. Int J Immunopathol Pharmacol 2009, 22(1):15-19.
3. Newschaffer C.J., Croen L.A., Daniels J., et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2007, 28:235-258.
4. Newschaffer C.J., Fallin D., Lee N.L. Heritable and nonheritable risk factors for autism spectrum disorders. Epidemiol Rev 2003, 24:137-153.
5. Guerra, DJ. The molecular genetics of autism spectrum disorders: genomic mechanisms, neuroimmunopathology, and clinical implications. Autism Res Treat, Article ID 398636, 2011. [accessed on 20.08.11]. http://www.hindawi.com.
6. Kim H.-G., Kishikawa S., Higgins A.W., et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 2008, 82:199-207.
7. Ylisaukko-oja T., Rehnström K., Auranen M., Vanhala R., et al. Analysis of four neuroligin genes as candidates for autism. Eur J Hum Genet 2005, 13:1285-1292.
8. Herbert M.R., Russo J.P., Yang S., et al. Autism and environmental genomics. Neurotoxicology 2006, 27:671-684.
9. Greenberg D.A., Hodge S.E., Sowinski J., Nicoll D. Excess of twins among affected sibling pairs with autism: implications for the etiology of autism. Am J Hum Genet 2001, 69:1062-1067.
10. Tint G.S., Irons M., Elias E.R., Batta A.K., Frieden R., Chen T.S., et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 1994, 330:107-113.
11. Sikora D.M., Pettit-Kekel K., Penfield J., Merkens L.S., Steiner R.D. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006, 140:1511-1518.
12. Wainwright G., Mascitelli L., Goldstein M.R. Cholesterol-lowering therapy and cell membranes. Stable plaque at the expense of unstable membranes?. Arch Med Sci 2009, 3:289-295.
13. Pike I.J. Rafts defined: a report on the keystone symposium on lipid rafts and cell function. J Lipid Res 2006, 47:1597-1598.
14. Tong J., Borbat P.P., Freed J.H., Shin Y.-K. A scissors mechanism for stimulation of SNARE-mediated lipid mixing by cholesterol. PNAS 2009, 106:5141-5146.
15. Saher G., Brügger B., Lappe-Siefke C., Möbius W., Tozawa R.-I., Wehr M.C., et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005, 8:468-475.
16. Craig A.M., Kang Y. Neurexin neuroligin signaling in synapse development. Curr Opin Neurobiol 2007, 17:43-52.
17. Palinski W. Maternal fetal cholesterol transport in the placenta: good, bad, and target for modulation. Circ Res 2009, 104:569-571.
18. Lin B., Kubushiro K., Akiba Y., et al. Alteration of acidic lipids in human sera during the course of pregnancy: characteristic increase in the concentration of cholesterol sulfate. J Chromatogr B 1997, 704:99-104.
19. Strott C.A. Cholesterol sulfate in human physiology: what's it all about?. J Lipid Res 2003, 44:1268-1278.
20. Langlais J., Zollinger M., Plante L., Chapdelaine A., Bleau G., Roberts K.D. Localization of cholesterol sulfate in human spermatozoa in support of a hypothesis for the mechanism of capacitation. Proc Natl Acad Sci USA 1981, 78:7266-7270.
21. Rodriguez W.V., Wheeler J.J., Klimuk S.K., Kitson C.N., Hope M.J. Transbilayer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes. Biochemistry 1995, 34:6208-6217.
22. Nakae H., Hanyu O., Fuda H., Strott C.A. Novel role of cholesterol sulfate in gene regulation during skin development. FASEB J 2008, 22:782.2.
23. Presland R.B. Function of filaggrin and caspase-14 in formation and maintenance of the epithelial barrier. Dermatol Sinica 2009, 27:1-14.
24. Palmer C.N., Ismail T., Lee S.P., et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007, 120:64-68.
25. Croen L.A., Grether J.K., Yoshika C.K., Odouly R., Van der Water J. Maternal auto-immune diseases, asthma and allergies, and childhood autism spectrum disorders. Arch Paediatr Adolesc Med 2005, 159:151-157.
26. Becker K.G. Autism, asthma, inflammation, and the hygiene hypothesis. Med Hypotheses 2007, 69:731-740.
27. Schuttelaar M.L.A., Kerkhof M., Jonkman M.F., et al. Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure. Allergy 2009, 64:1758-1765.
28. Magalhäes E.S., Pinto-Mariz F., Bastos-Pinto S., Pontes A.T., Prado E.A., de Azevedo L.C. Immune allergic response in Asperger syndrome. J Neuroimmunol. 2009, 216:108-112.
29. Dawson P.A. Sulfate in fetal development. Semin Cell Dev Biol 2011, 22:653-659.
30. Klüppel M. The roles of chondroitin-4-sulfotransferase-1 in development and disease. Prog Mol Biol Transl Sci 2010, 93:113-132.
31. Chen C.-P., Liu S.-H., Lee M.-Y., Chen Y.-Y. Heparan sulfate proteoglycans in the basement membranes of the human placenta and decidua. Placenta 2008, 29:309-316.
32. Coughtrie M.W., Bamforth K.J., Sharp S., et al. Sulfation of endogenous compounds and xenobiotics-interactions and function in health and disease. Chem Biol Interact 1994, 92:247-256.
33. Becker K.G., Schultz S.T. Similarities in features of autism and asthma and a possible link to acetaminophen use. Med Hypotheses 2010, 74:7-11.
34. Axelson M. 25-Hydroxyvitamin D3 3-sulphate is a major circulating form of vitamin D in man. FEBS Lett 1985, 191:171-175.
35. McNally M.E., Atkinson S.A., Cole D.E.C. Contribution of sulfate and sulfoesters to total sulfur intake in infants fed human milk. J Nutr 1991, 121:1250-1254.
36. Baron-Cohen S. The extreme male brain theory of autism. Trends Cogn Sci 2002, 6:248-254.
37. Fields C. From 'Oh, OK' to 'Ah, yes' to 'Aha!': hyper-systemizing and the rewards of insight. Personality Individ Differ 2011, 50:1159-1167.
38. Hediger M.L., England L.J., Molloy C.A., Yu K.F., Manning-Courtney P., Mills J.L. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord 2008, 38:848-856.
39. Muir M., Romalo G., Wolf L., Elger W., Schweikert H.-U. Estrone sulfate is a major source of local estrogen formation in human bone. J Clin Endocrinol Metab 2004, 89:4685-4692.
40. Sarachana T., Xu M., Wu R.-C., Hu V.W. Sex hormones in autism: androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. PLoS ONE 2011, 6:e17116.
41. Strous R.D., Golubchik P., Maayan R., et al. Lowered DHEA-S plasma levels in adult individuals with autistic disorder. Eur Neuropsychopharmacol 2005, 15:305-309.
42. Croonenberghs J., Spaas K., Wauters A., et al. Faulty serotonin-DHEA interactions in autism: results of the 5-hydroxytryptophan challenge test. Neuro Endocrinol Lett 2008, 29:385-390.
43. Geier D.A., Kern J.K., Garver C.R., Adams J.B., Audhya T., Geier M.R. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 2009, 34:386-393.
44. Genuis S.J., Bouchard T.P. Celiac disease presenting as autism. J Child Neurol 2010, 25:114-119.
45. Banks W.A., Kastin A.J. Peptide transport systems for opiates across the blood-brain barrier. Am J Physiol 1990, 259:E1-E10.
46. Zioudrou C., Streaty R.A., Klee W.A. Opioid peptides derived from food proteins: the exorphins. J Biol Chem 1979, 254:2446-2449.
47. Shattock P., Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Targets 2002, 6:175-183.
48. Murch S.H., MacDonald T.T., Walker-Smith J.H., Levin M., Lionnettti P., Klein N.J. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993, 1:711-714.
49. Waring R.H., Klovrza L.V. Sulphur metabolism in autism. J Nutr Environ Med 2000, 10:25-32.
50. Fernandes I., Hampson G., Cahours X., et al. Abnormal sulfate metabolism in vitamin D-deficient, rats. J Clin Invest 1997, 100:2196-2203.
51. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
52. Michel T., Feron O. Nitric oxide synthases: which, where, how, and why?. J Clin Invest 1997, 100:2146-2152.
53. Aschner J.L., Zeng H., Kaplowitz M.R., Zhang Y., Slaughter J.C., Fike C.D. Heat shock protein 90-eNOS interactions mature with postnatal age in the pulmonary circulation of the piglet. Am J Physiol Lung Cell Mol Physiol 2009, 296:L555-L564.
54. Hislop A.A., Springall D.R., Buttery L.D., Pollock J.S., Haworth S.G. Abundance of endothelial nitric oxide synthase in newborn intrapulmonary arteries. Arch Dis Child Fetal Neonatal Ed 1995, 73:F17-F21.
55. Higashi Y., Fuda H., Yanai H., Lee Y., Fukushige T., Kanzaki T., et al. Expression of cholesterol sulfotransferase (SULT2B1b) in human skin and primary cultures of human epidermal keratinocytes. J Invest Dermatol 2004, 122:1207-1213.
56. Yanai H., Javitt N.B., Higashi Y., Fuda H., Strott C.A. Expression of cholesterol sulfotransferase (SULT2B1b) in human platelets. Circulation 2004, 109:92-96.
57. Kleinbongard P., Schulz R., Rassaf T., et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006, 107:2943-2951.
58. Li H., Raman C.S., Glaser C.B., et al. Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem 1999, 274:21276-21284.
59. Stroes E., Hijmering M., van Zandvoort M., Wever R., Rabelink T.J., van Faassen E.E. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett 1998, 438:161-164.
60. García-Cardeña G., Martasek P., Siler Masters B.S., et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin: functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997, 272:25437-25440.